Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

INDP Indaptus Therapeutics

Watchlist
2.1600.0000.00%
Close 09/30 16:00 ET
Giving away premium quotes worth 5000 HKD/year to unlock more data
Get NOW
High
2.260
Open
2.203
Turnover
4.73K
Low
2.160
Pre Close
2.160
Volume
2.15K
Market Cap
17.84M
P/E(TTM)
Loss
52wk High
8.174
Shares
8.26M
P/E(Static)
Loss
52wk Low
1.890
Float Cap
9.93M
Bid/Ask %
33.33%
Historical High
1600.000
Shs Float
4.59M
Volume Ratio
0.26
Historical Low
1.890
Dividend TTM
--
Div Yield TTM
--
P/B
0.59
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.05%
Amplitude
4.63%
Avg Price
2.194
Lot Size
1
Float Cap
9.93M
Bid/Ask %
33.33%
Historical High
1600.000
Shs Float
4.59M
Volume Ratio
0.26
Historical Low
1.890
Dividend TTM
--
P/B
0.59
Dividend LFY
--
Turnover Ratio
0.05%
Amplitude
4.63%
Avg Price
2.194
Lot Size
1
Price Forecast

No Data

News

Comment

No Data

Company Overview More
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.
CEO: Meckler, Jeffrey A.
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top